Abstract
Mutations in the LRRK2 gene have been implicated in the pathogenesis of Parkinsons disease. This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinsons disease-associated mutants do not appear to have reduced GTP hydrolysis activities.
Keywords: LRRK2, ROC domain, small GTPase, GTP binding, Parkinson's disease
Protein & Peptide Letters
Title: The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein
Volume: 16 Issue: 12
Author(s): Qing-Shan Fu, Ai-Xin Song, Su-Xia Li and Hong-Yu Hu
Affiliation:
Keywords: LRRK2, ROC domain, small GTPase, GTP binding, Parkinson's disease
Abstract: Mutations in the LRRK2 gene have been implicated in the pathogenesis of Parkinsons disease. This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinsons disease-associated mutants do not appear to have reduced GTP hydrolysis activities.
Export Options
About this article
Cite this article as:
Fu Qing-Shan, Song Ai-Xin, Li Su-Xia and Hu Hong-Yu, The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein, Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839386
DOI https://dx.doi.org/10.2174/092986609789839386 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Intra and Extracellular Protein Interactions with Tau
Current Alzheimer Research VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Meet Our Editorial Board Member:
Protein & Peptide Letters Benzimidazole Derivatives as Kinase Inhibitors
Current Medicinal Chemistry Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases
Current Pharmaceutical Design Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Editorial: Spatial Cognition in Normal Aging, MCI and AD
Current Alzheimer Research Alzheimers Disease and Immunotherapy
Current Alzheimer Research Isoflurane Facilitates Synaptic NMDA Receptor Endocytosis in Mice Primary Neurons
Current Molecular Medicine Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Pharmacogenetic Approach to Treating Drug Dependence: Serotonin Transporter Gene (SLC6A4) Promoter Polymorphisms as Treatment Predictors in Jordanian Arabs
Current Pharmacogenomics and Personalized Medicine The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry